📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Excel Industries Corrects Q2 FY26 EPS from 41.90 to 14.90 Following NSE Query
Excel Industries Limited has issued a clarification regarding a reporting error in its financial results for the quarter ended September 30, 2025. The company admitted that the Earnings Per Share (EPS) was incorrectly stated as 41.90 in the XBRL filing due to an inadvertent error. The actual EPS for the period is 14.90, which is significantly lower than the figure previously recorded in the exchange's digital format. The company has now submitted the corrected XBRL filing to the National Stock Exchange.
Key Highlights
Standalone EPS for the quarter ended September 30, 2025, revised from 41.90 to 14.90
Clarification issued in response to a discrepancy notice from the National Stock Exchange (NSE)
The error was attributed to an inadvertent mistake during the XBRL filing process
Revised XBRL data has been uploaded to the NEAPS portal to reflect the correct financial metrics
💼 Action for Investors
Investors should update their financial models to reflect the corrected EPS of 14.90 for the September 2025 quarter. While this is a clerical correction, the significant difference in the figures warrants a more cautious look at the company's internal reporting controls.
Loading analysis...
Excel Industries Q3 Net Profit Rises 31% YoY to ₹8.40 Cr; Revenue Up 19%
Excel Industries reported a 19% YoY growth in revenue from operations to ₹233.45 crore for the quarter ended December 31, 2025. Net profit for the quarter increased by 31.3% YoY to ₹8.40 crore, showing a recovery from the previous year's quarterly performance. However, for the nine-month period, net profit declined by 15.8% YoY to ₹60.69 crore, indicating some margin pressure earlier in the fiscal year. The company has also reorganized its reporting into a single 'Chemicals' segment and made a one-time provision of ₹1.15 crore for gratuity due to new Labour Codes.
Key Highlights
Quarterly Revenue from operations grew 18.8% YoY to ₹233.45 crore from ₹196.41 crore.
Net Profit for Q3 FY26 stood at ₹8.40 crore, up from ₹6.40 crore in the same period last year.
Nine-month (9M) Revenue increased to ₹813.12 crore compared to ₹730.23 crore in the previous year.
The company transitioned to a single operating and reportable segment named 'Chemicals' for better strategic focus.
An incremental provision of ₹115.42 lakhs was made for Gratuity following the notification of new Government Labour Codes.
💼 Action for Investors
The quarterly recovery in profit and revenue growth is a positive signal, though the year-to-date profit decline warrants a cautious outlook on overall margin stability. Investors should monitor if the new single-segment focus improves operational efficiency in upcoming quarters.
Loading analysis...
Excel Industries Q3 FY26 Revenue Rises 19% to ₹233 Cr; PAT Up 31% YoY
Excel Industries reported a strong Q3 FY26 with revenue growing 19% YoY to ₹233 crore, driven by improved demand in performance solutions and better price realizations. While quarterly PAT rose 31% to ₹8 crore, the 9-month performance shows a cumulative decline in profitability with 9M PAT down 16% YoY to ₹61 crore. The company is planning a significant capital expenditure of ₹200-300 crore over the next three years for capacity expansion and technology upgrades. Export contributions remain steady, accounting for 27% of quarterly revenue.
Key Highlights
Q3 FY26 Revenue grew 19% YoY to ₹233 Cr, while Adjusted EBITDA rose 39% to ₹17 Cr.
9M FY26 Revenue increased 11% to ₹813 Cr, though PAT declined 16% to ₹61 Cr compared to the previous year.
Planned Capex of ₹200-300 Cr over the next 3 years for plant upgrades, product innovation, and capacity expansion.
Adjusted EBITDA margin for Q3 FY26 improved by 100bps YoY to 7.3% due to favorable product mix.
Export revenue contributed 27% to the total revenue in Q3 FY26, up from 22.3% for the 9-month period.
💼 Action for Investors
Investors should monitor the execution of the ₹200-300 crore capex plan and the recovery in 9-month profitability margins. The strong quarterly growth in performance solutions and biocides suggests a positive turnaround in demand that needs to be sustained.
Loading analysis...
Excel Industries Approves Unaudited Financial Results for Q3 FY2025-26
Excel Industries Limited has officially approved its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors met on February 3, 2026, for over four and a half hours to review and finalize the performance metrics. The submission includes the statutory Limited Review Report, ensuring regulatory compliance under SEBI guidelines. While the cover letter does not disclose specific profit figures, it confirms the completion of the audit committee's review process.
Key Highlights
Board approved financial results for the quarter and nine months ended December 31, 2025.
The Board meeting lasted approximately 4 hours and 40 minutes, concluding at 06:40 p.m.
Results were reviewed and recommended by the Audit Committee prior to Board approval.
The filing includes the Limited Review Report issued by the company's statutory auditors.
The announcement covers both Chemicals and Environment & Biotech divisions.
💼 Action for Investors
Investors should examine the detailed financial tables attached to the full report to evaluate margin performance in the chemical segment. Compare the year-on-year growth for the nine-month period ending December 2025 to assess the company's recovery or growth trajectory.
Loading analysis...
Excel Industries Approves Q3 FY26 Unaudited Financial Results
Excel Industries Limited's Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, during their meeting on February 3, 2026. The results were reviewed and recommended by the Audit Committee prior to board approval. While the specific financial figures were not detailed in the cover letter, the announcement confirms the completion of the statutory review for the third quarter. The board meeting concluded at 6:40 p.m. following a nearly five-hour session.
Key Highlights
Board approved unaudited financial results for the quarter ended December 31, 2025.
Financial results for the nine-month period ending December 31, 2025, were also cleared.
The Audit Committee conducted a prior review and recommendation of the financials.
A Limited Review Report from the statutory auditors has been filed with the results.
The board meeting lasted approximately 4 hours and 40 minutes.
💼 Action for Investors
Investors should closely examine the detailed financial tables and the Limited Review Report to evaluate the company's margin performance and revenue growth. Compare these results against industry peers in the chemicals and biotech sectors to assess relative performance.